Top

Published in:

01-07-2007 | Original Article

Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications

Authors: Daehoon Park, Rolf Kåresen, Tove Noren, Torill Sauer

Published in: Virchows Archiv | Issue 1/2007

Abstract

Proliferative activity of tumour cells assessed by immunohistochemical Ki-67 expression is one of several prognostic indicators in breast cancer. The major objective of this study was to investigate the prognostic impact of Ki-67 proliferative activity in the axillary lymph node metastases and in the matched primary breast carcinoma from 194 patients. There was a statistically significant up-regulation of Ki-67 protein in the metastatic deposit compared to where the primary tumour was found (p = 0.001). A low Ki-67 index in both the primary and the metastatic tumours was a favorable prognostic factor. A high index in both primary and metastatic lesion and an up-regulation from a low index in the primary tumour to a high index in the metastatic deposit represented an unfavorable prognostic factor. Multivariate analysis showed that Ki-67 expression in the metastases was a superior independent prognostic factor of clinical outcomes compared to that in the primary tumours. Ki-67 expression in ≥10% of carcinoma cells in the primary tumours and ≥15% in the nodal metastases seems to be optimal cut-off levels. Ki-67 is of value as an independent prognostic factor in breast cancer.

Beenken SW, Bland KI (2002) Biomarkers for breast cancer. Minerva Chir 57:437–448PubMed

Betta PG, Robutti F, Pilato FP, Spinoglio G, Bottero G (1989) Correlation of proliferative activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol 10:433–437PubMed

Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947PubMed

Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27:137–142PubMedCrossRef

Buxant F, Anaf V, Simon P, Fayt I, Noel JC (2002) Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 75:1–3PubMedCrossRef

Campani D, De-Negri F, Fabbri R, Martini L, Giani C, Squartini F, Sarnelli R (1991) Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers 6:144–150PubMed

Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723–1739PubMedCrossRef

Di-Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Marinozzi V (1991) A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67:463–471PubMedCrossRef

Ding SL, Sheu LF, Yu JC, Yang TL, Chen B, Leu FJ, Shen CY (2004) Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 11:911–919PubMed

10.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

11.

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978PubMed

12.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed

13.

Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–682PubMedCrossRef

14.

Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HF (1998) MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460–465PubMed

15.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRef

16.

Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO (1992) Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 18:224–229PubMed

17.

Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J (2004) Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 100:455–464PubMedCrossRef

18.

Offersen BV, Sorensen FB, Knoop A, Overgaard J (2003) The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43:573–582PubMedCrossRef

19.

Paradiso A, Tommasi S, Barletta A, Leone B, Lacava J, Vellejo C, Labriola A, Marzullo F, Altieri R, Schittulli F, De Lena M (1999) Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients. Anticancer Res 19:4523–4528PubMed

20.

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef

21.

Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW, Ellis IO (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149PubMed

22.

Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG (1991) Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68:549–557PubMedCrossRef

23.

Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322PubMedCrossRef

24.

Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U (1995) Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697–704PubMed

25.

Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 15:2151–2159CrossRef

26.

Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR (2002) Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 98:118–127PubMedCrossRef

27.

Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18:374–381PubMedCrossRef

28.

Tavassoli FA, Devilee P (2003) Tumours of the breast. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs (World Health Organization Classification of Tumours series 5). IARC, Lyon, pp 9–112

29.

Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA (2003) Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker? Cancer 97:1321–1331PubMedCrossRef

30.

Veronese SM, Gambacorta M (1991) Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95:30–34PubMed

31.

Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S (1991) Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421–428PubMedCrossRef

32.

Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH (1989) Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology 46:255–259PubMedCrossRef

33.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:24–30CrossRef

Title: Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications
Authors: Daehoon Park
Rolf Kåresen
Tove Noren
Torill Sauer
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 1/2007
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0435-2

ACC 2024 Congress

Springer Medicine

Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Epithelial atypia in biopsies performed for microcalcifications. Practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up

Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells

Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions

Response from authors of “Extracellular matrix alterations in conventional renal cell carcinomas by tissue microarray profiling influenced by the persistent, long-term, low-dose ionizing radiation exposure in humans”

Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-γ receptor 2 deficiency

Hodgkin’s lymphoma in a patient with Jo-1 syndrome